Virax Biolabs Group annual return on equity
2023
2024
2025
2026
Virax Biolabs Group Return on Equity (ROE) Growth & History (VRAX)
Virax Biolabs Group's return on equity was −75.70% for fiscal 2026.
View full Virax Biolabs Group company overviewVirax Biolabs Group annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2026 | 2026-03-31 | −75.70% | +33.99 pp |
| 2025 | 2025-03-31 | −109.69% | −16.69 pp |
| 2024 | 2024-03-31 | −93.00% | +40.91 pp |
| 2023 | 2023-03-31 | −133.90% | — |
Virax Biolabs Group return on equity trends
Between the periods ended 2023-03-31 and 2026-03-31, Virax Biolabs Group's return on equity increased from −133.90% to −75.70%, a change of +58.21 percentage points.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Virax Biolabs Group source filings ↗